GlaxoSmithKline LLC et al v. Teva Pharmaceuticals USA Inc.

  1. March 06, 2025

    Don't Give Teva 'Eighth Bite' At $235M Patent Trial, GSK Says

    GlaxoSmithKline has told a Delaware federal judge that Teva's request for a new trial in the drugmakers' decade-long, $235 million "skinny label" patent fight over heart failure medication is an "eighth bite at the same apple."

  2. February 11, 2025

    Teva Says Mixed Coreg Rulings Undermine GSK Damages Bid

    Teva Pharmaceuticals has urged a Delaware federal judge to reject GlaxoSmithKline's request to enhance a $235 million infringement award over a skinny label version of GSK's cardiovascular drug Coreg, saying judges at all levels of courts made clear the case wasn't open and shut.

  3. January 28, 2025

    GSK Urges Del. Judge To Enhance $235M Skinny Label Win

    GlaxoSmithKline LLC is urging a Delaware federal judge to enhance the $235 million damages award a jury issued against Teva Pharmaceuticals USA Inc. in 2017, now that the dispute over skinny label infringement has returned to district court.

  4. December 13, 2024

    What's Left In $400M Skinny Label Row? A Lot, Court Says

    A number of key issues remain live in the $400 million fight between Teva Pharmaceuticals and GlaxoSmithKline over whether the generic-drug maker induced healthcare providers to infringe the brand-name company's heart drug patent, including the availability of a new trial, a Delaware federal judge has said.

  5. July 11, 2024

    GSK Asks Judge To Rule In Teva IP Case, Citing Opioid Deals

    A GlaxoSmithKline lawyer has urged a Delaware federal judge to make up his mind about a nearly $400 million patent case against Teva Pharmaceuticals in light of unrelated "opioid-related cases" that the Israeli generic-drug maker has been settling in the billions of dollars.

  6. March 28, 2018

    Teva Skirts $235M Infringement Verdict In Coreg Patent Row

    A Delaware federal judge on Wednesday released Teva Pharmaceutical Industries Ltd. from a $235 million verdict over its generic version of GlaxoSmithKline LLC's heart medication Coreg, finding Teva did not infringe a patent covering the drug.

  7. October 26, 2017

    GSK, Teva See Bigger Issues Than Cash In $235M Award Fight

    Attorneys for GlaxoSmithKline and Teva Pharmaceuticals both told a Delaware federal judge on Thursday that far more than money is at stake in post-trial challenges to a $235 million heart drug infringement award won by GSK in June.

  8. August 28, 2017

    $235M Patent Award Spurs Teva Redo Request, GSK Fees Bid

    One month after a Delaware federal jury found Teva Pharmaceuticals willfully infringed a patent tied to the hypertension drug Coreg and handed GlaxoSmithKline a $235 million verdict, Teva on Friday pushed for the court to grant it judgment or a new trial, and GSK asked for enhanced damages and attorney fees.

  9. June 21, 2017

    GSK Wins $235M Verdict Against Teva In Coreg Patent Fight

    Teva Pharmaceuticals USA Inc. should pay GlaxoSmithKline LLC more than $235 million for willfully infringing a patent tied to the hypertension drug Coreg, a Delaware federal jury said.